3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neurofibromatosis 1
2
Glioma
2
Colorectal Neoplasms
2
Vascular Malformations
1
Skin Diseases, Vascular
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Oligodendroglioma
1
Neurofibromatoses
1
Neurofibroma
1
Neurocytoma
1
Neoplasms, Neuroepithelial
1
NF1
1
Melanoma
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Lymphangioma
1
Liposarcoma, Myxoid
1
Liposarcoma
1
KRAS Mutant Non-Small Cell Lung Cancer
1
Glioblastoma
1
Ganglioneuroma
1
Ganglioglioma
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Astrocytoma
1
Arteriovenous Malformations
1
Interventions
Temozolomide
264
Radiotherapy
119
Bevacizumab
105
Magnetic Resonance Spectroscopy
59
Radiation
47
pembrolizumab
30
Irinotecan
28
Surgical Procedures, Operative
23
Lomustine
21
Specimen Handling
19
Nivolumab
19
Radiosurgery
18
Carmustine
18
Aminolevulinic Acid
16
Erlotinib Hydrochloride
15
Drug Therapy
15
Blood Specimen Collection
14
Radiotherapy, Intensity-Modulated
13
O(6)-benzylguanine
13
Chemotherapy, Adjuvant
13
Carboplatin
13
Filgrastim
11
Cyclophosphamide
11
sargramostim
10
poly ICLC
10
atezolizumab
10
Thalidomide
10
Etoposide
10
Ipilimumab
9
Everolimus
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Glioblastoma
×
mirdametinib
×
Clear all
NCT07521657
2026-04-13
NF118
University of Alabama at Birmingham
Phase 2
Not yet recruiting
55 enrolled